US approves first generic competitor to Mylan's EpiPen

August 16, 2018
Mylan Pharmaceuticals, which makes the EpiPen, faced an outpouring of criticism after it raised the price of a pack up two to $600 in 2016. The same package cost $100 in 2008

US regulators Thursday approved the first generic alternative for the EpiPen, a life-saving emergency allergy medicine, two years after soaring prices for the original version owned by Mylan stoked controversy.

The US Food and Drug Administration granted approval to Israel-based Teva Pharmaceuticals to market its generic epinephrine auto-injector for treatment of allergic reactions.

"Today's approval of the first generic version of the most-widely prescribed epinephrine auto-injector in the US is part of our longstanding commitment to advance access to lower cost, safe and effective generic alternatives once patents and other exclusivities no longer prevent approval," said FDA Commissioner Scott Gottlieb.

Mylan Pharmaceuticals, which makes the EpiPen, faced an outpouring of criticism after it raised the price of a pack up two to $600 in 2016. The same package cost $100 in 2008.

Mylar then introduced its own generic alternative late in 2016 at a cost of $300.

Teva did not immediately say how much its product would cost or when it would be available. Its shares rose six percent on the news.

The EpiPen is designed to automatically inject a dose of epinephrine into a person's thigh to stop an allergic reaction, whether to bee stings, peanuts or other foods, medications, latex or other causes.

Anaphylaxis is "a medical emergency that affects the whole body and, in some cases, leads to death," affecting about one in 50 Americans, the FDA said.

People who have suffered from anaphylaxis once face a continual risk of another episode and must carry an emergency dose of at all times.

Explore further: FDA approves new, cheaper rival to EpiPen allergy shot

Related Stories

FDA approves new, cheaper rival to EpiPen allergy shot

June 16, 2017
U.S. regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical company greed.

Defect prompts Mylan to recall some Epipens

April 3, 2017
(HealthDay)—Mylan, the maker of the Epipen, says it is recalling "select lots" of the device used to treat dangerous allergic reactions due to a defect that might render it "difficult to activate in an emergency."

Affected by the EpiPen shortage? Here's what to do

May 9, 2018
(HealthDay)—Production issues have made EpiPens hard to find in some areas of the United States, the U.S. Food and Drug Administration announced Wednesday.

Needed: an 'action plan' for kids prone to severe allergic reactions

February 13, 2017
(HealthDay)—When kids are at risk of severe allergic reactions, all their caregivers should have a written action plan and epinephrine auto-injectors readily available, according to new reports from the American Academy ...

After harsh light, a cheaper version of EpiPen from Mylan

December 16, 2016
Mylan is releasing a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew scorn from parents nationwide and spawned Congressional inquiries.

Pediatric allergist discusses EpiPen controversy

August 26, 2016
Members of Congress are calling for an investigation into the EpiPen maker Mylan. The pharmaceutical company has increased the price of EpiPens, from about $100 in 2008 to more than $500 today.

Recommended for you

Drug overdose epidemic goes far beyond opioids, requires new policies

November 7, 2018
Most government-funded initiatives to address the overdose epidemic in the United States have targeted opioids specifically and have neglected other drugs that are increasingly implicated in overdoses, such as cocaine and ...

Zebrafish larvae help in search for appetite suppressants

November 2, 2018
Researchers at the University of Zurich and Harvard University have developed a new strategy in the search for psychoactive drugs. By analyzing the behavior of larval zebrafish, they can filter out substances with unwanted ...

FDA OKs powerful opioid pill as alternative to IV painkiller

November 2, 2018
U.S. regulators on Friday approved a fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals.

Amphetamine-related hospitalizations surged between 2003 and 2015

November 2, 2018
An analysis conducted by Hennepin Healthcare, University of Minnesota School of Public Health and University of Michigan researchers shows amphetamine-related hospitalizations increased more than 270 percent from 2008 to ...

Cocaine-fentanyl overdoses underscore need for more 'test strips' and rapid response

November 1, 2018
Penn Medicine emergency department physicians are calling for more readily available testing strips to identify the presence of fentanyl in patients experiencing a drug overdose, and a rapid, coordinated response among health ...

Combination drug targeting opioid system may help relieve symptoms of major depression

October 29, 2018
Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment. The results of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.